Published studies have reported that an inflammatory bowel disease (IBD) phenotype co-occurs frequently in children with autism spectrum disorder (ASD) having chronic gastrointestinal (GI) symptoms. Ileocolitis(inflammation of ileum and colon) is a frequent finding in GI symptomatic children with ASD undergoing diagnostic ileo- colonoscopy and, in our clinical experience, is the cause of the GI symptoms. Published data have consistently shown that active gastrointestinal symptoms can affect behavior, sleep, anxiety levels, as well as the severity of core ASD features. In fact, the severity of GI symptoms in many patients is more concerning to the parents than the autism itself and more severely impacts quality of life. Pharmaceutical treatment of ASD-associated IBD largely resolves GI symptoms. To date, clinical and behavioral outcomes following treatment of ASD-associated IBD have not yet been systematically evaluated, documented, analyzed, and reported. The talks in this two-part lecture will discuss: (1) the rationale for, and development of, a treatment study to assess changes that occur in children with autism that are treated for ileocolonic inflammation (Dr. Krigsman), and (2) the findings in the first 11 participants to complete this 52-week trial (Dr. Walker).
Speaker: Steve Walker, PhD